Vasopressin as adjunctive therapy in pulmonary hypertension associated with refractory systemic hypotension in term newborns

Simple item page
dc.catalogadoraba
dc.contributor.authorSantelices Ruíz, Felipe
dc.contributor.authorMasoli, Daniela
dc.contributor.authorKattan Said, Alberto Javier
dc.contributor.authorToso, Alberto
dc.contributor.authorLuco Illanes, Matías Fernando
dc.date.accessioned2024-01-17T19:36:09Z
dc.date.available2024-01-17T19:36:09Z
dc.date.issued2022
dc.description.abstractAbstract Objective. The aim of our study is to describe the effects of vasopressin on term infants with persistent pulmonary hypertension under a standardized protocol. Study Design: In 2019, we designed a standardized protocol for the management of refractory hypotension in the context of pulmonary hypertension, which included the use of vasopressin. This is a retrospective cohort study to evaluate the clinical, laboratory, and echocardiographic outcomes of patients who required vasopressin in the context of this new protocol in a referral level IV neonatal intensive care unit. Results: We included 48 neonates with a median gestational age of 37 weeks in a period of 30 months (December 2019 to May 2022). Congenital diaphragmatic hernia was the main cause of persistent pulmonary hypertension in this cohort (82%). All patients were on mechanical ventilation and receiving inhaled nitric oxide. In our cohort at 4 hours after initiation of vasopressin, blood pressure, serum pH, and urinary output increased significantly. The vasoactive inotropic score, lactate and oxygenation index decreased. Echocardiographic follow-up also showed a decrease in the relative pressure of the right ventricle and an improvement in the cardiac output of both ventricles. There were no episodes of severe hyponatremia (<120 mmol/L). Discussion: This study showed that the use of vasopressin in neonates with persistent pulmonary hypertension and refractory systemic hypotension was associated with a rapid and significant improvement in oxygenation and hemodynamic markers of perfusion, including blood pressure. This association was early during the first hours of treatment and vasopressin was safely withdrawn after a median of 3 days of treatment.
dc.fechaingreso.objetodigital2024-01-19
dc.format.extent12 páginas
dc.fuente.origenORCID-ene24
dc.identifier.doi10.21203/rs.3.rs-2203038/v1
dc.identifier.eissn2693-5015
dc.identifier.urihttps://doi.org/10.21203/rs.3.rs-2203038/v1
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/80595
dc.information.autorucEscuela de Medicina; Toso, Alberto; 0000-0002-3809-2567; 238020
dc.information.autorucEscuela de Medicina; Santelices Ruíz, Felipe; 0000-0002-9229-221X; 209536
dc.information.autorucEscuela de Medicina; Masoli, Daniela; S/I; 209537
dc.information.autorucEscuela de Medicina; Kattan Said, Alberto Javier; 0000-0002-2911-5982; 53324
dc.information.autorucEscuela de Medicina; Luco Illanes, Matías Fernando; 0000-0002-7698-8065; 7023
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final12
dc.pagina.inicio1
dc.revistaResearch Square
dc.rightsacceso abierto
dc.rights.licenseCC BY 4.0 DEEDAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleVasopressin as adjunctive therapy in pulmonary hypertension associated with refractory systemic hypotension in term newborns
dc.typepreprint
sipa.codpersvinculados238020
sipa.codpersvinculados209536
sipa.codpersvinculados209537
sipa.codpersvinculados53324
sipa.codpersvinculados7023
sipa.trazabilidadORCID;2024-01-08
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
E3A56E~1.PDF
Size:
339 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas